Biocon Biologics, Viatris receive EC approval for biosimilar insulin aspart Kixelle

This follows the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency, a Biocon statement said on Friday.

Neutral Biocon; target of Rs 385: Motilal Oswal

Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 385 in its research report dated January 22, 2021.

Buy Biocon; target of Rs 470: Sharekhan

Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 470 in its research report dated January 22, 2021.

Hold Biocon; target of Rs 450: ICICI Direct

ICICI Direct recommended hold rating on Biocon with a target price of Rs 450 in its research report dated January 22, 2021.

Biocon may further defer biologics business IPO, says Kiran Mazumdar Shaw

Biocon’s revenue from the biologics business in Q3FY21 was Rs 769 Crore, a 11 percent increase year-on-year and 14 percent rise quarter-on-quarter, Biocon said in a BSE filing.

Biocon share price falls 2% after CLSA retains sell on stock

CLSA has retained sell on the stock and has cut target to Rs 240 from Rs 260 per share

Biocon Q3 net profit falls 19% to Rs 186.6 crore

Expenses rose to Rs 1,642.6 crore for the December quarter, an increase of 14.52 percent, as against Rs 1,434.3 crore in the year-ago period.

Biocon Consolidated December 2020 Net Sales at Rs 1,851.00 crore, up 5.89% Y-o-Y

Biocon Standalone December 2020 Net Sales at Rs 456.10 crore, down 9.02% Y-o-Y

Biocon share price falls 9% after Q3 profit dips 18% YoY to Rs 186 crore

The generics business reported a 3 percent dip in the third quarter at Rs 561 crore, as against Rs 576 crore in the corresponding period last year.

Biocon Q3 PAT may dip 1.5% YoY to Rs. 199.7 cr: ICICI Direct

Net Sales are expected to increase by 15.4 percent Y-o-Y (up 15.7 percent Q-o-Q) to Rs. 2,018.1 crore, according to ICICI Direct.

Biocon shares up 2% after ADQ pumps Rs 555 crore in subsidiary

The transaction is subject to customary condition precedents and approvals. Post the completion of this transaction, Biocon Ltd will hold 89.89 percent stake in Biocon Biologics on a fully diluted basis, the company said.

Sovereign wealth fund ADQ to invest $75 million in Biocon Biologics, deal values firm at around $4 billion

The current investment has put the post-money valuation of Biocon Biologics at ~$4.17 billion, said Kiran Mazumdar-Shaw, Executive Chairperson of Biocon

Buy Biocon: target of Rs 520: Sharekhan

Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 520 in its research report dated December 28, 2020.

Biocon share price rises 2% on launch of Tacrolimus capsules in US

The share touched its 52-week high Rs 487.70 and 52-week low Rs 235.80 on 23 December, 2020 and 19 March, 2020, respectively.

Biocon share price slips after CLSA retains 'sell' call, expects stock to dip to Rs 250

Biocon Biologics, and Mylan have been informed by the US health regulator of deferred action on the biologics licence application for a biosimilar to drug Avastin, used to treat various types of cancers, Biocon said.

Her father's daughter: Avani Singh focuses on the low-cost model of Ajay Singh's SpiceJet to disrupt COVID-19 testing market

Avani, daughter of SpiceJet Chairman & MD Ajay Singh, is the CEO of SpiceHealth

Kotak Wealth Hurun - Leading Wealthy Women's 2nd edition | HCL Technologies' Roshni Nadar is the wealthiest Indian woman; here's the full list

With a net worth of Rs 54,850 crore, HCL Technologies Chairperson Roshni Nadar Malhotra is India's richest women in 2020, according to a study by Kotak Wealth and Hurun India. Biocon Chairperson Kiran Mazumdar-Shaw is the second-richest woman on the list, with a net worth of 36,600 crore, followed by Leena Gandhi Tewari, Chairperson of USV (Rs 21,340 crore). The cumulative wealth of the 100 women on the list is Rs 2.73 lakh crore, the study said. Here are India's richest women in 2020, as per the Kotak Wealth Hurun list:

Roshni Nadar tops Kotak Wealth and Hurun India's list of richest women

Biocon Chairperson Kiran Mazumdar-Shaw is the second-richest woman on the list, with a net worth of 36,600 crore

Need global partnerships to become atmanirbhar, says Kiran Mazumdar-Shaw: Report

To attain self-reliance, Indian companies still need to harness innovation through international partnerships and collaborations, Kiran Mazumdar-Shaw has said.

Laurus Labs: Foray into biotech adds new lever of growth; accumulate

Efforts to diversify will open up new opportunities for Laurus Labs and make it move towards a higher-margin trajectory

IPO-bound Biocon Biologics in talks with Abu Dhabi fund ADQ to raise fresh capital

If the negotiations fructify— coming two weeks after the Goldman Sachs deal—it would mark the fourth successive investment in the Kiran Mazumdar Shaw-led Biocon unit in 2020.The last fundraise was struck at a valuation of $3.94 billion.

ZS PRIZE: Healthcare innovation challenge seeks ideas for Rs 1 crore prize money

ZS PRIZE is open to students and professionals from the start-up, enterprise, and NGO sectors of India. Indian citizens above the age of 18 can submit their ideas or solution prototypes till December 21, 2020

Goldman Sachs to invest $150 million in Biocon's IPO-bound subsidiary Biocon Biologics

As per the terms of the proposed agreement, Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion. The transaction is subject to customary approvals and conditions

Neutral Biocon; target of Rs 400: Motilal Oswal

Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 400 in its research report dated October 23, 2020.